CSPOR
乳癌
Lancet Oncol . 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial Masakazu Toi , Shigeru Imoto , Takanori Ishida , Yoshinori Ito , Hiroji Iwata , Norikazu Masuda , Hirofumi Mukai , Shigehira Saji , Akira Shimizu , Takafumi Ikeda , Hironori Haga , Toshiaki Saeki , Kenjiro Aogi , Tomoharu Sugie , Takayuki Ueno , Takayuki Kinoshita , Yuichiro Kai , Masahiro Kitada , Yasuyuki Sato , Kenjiro Jimbo , Nobuaki Sato , Hiroshi Ishiguro , Masahiro Takada , Yasuo Ohashi , Shinji Ohno
肺癌
Japanese Journal of Clinical Oncology, hyac032, Published: 22 March 2022
Article Navigation Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial)(仲 剛:国立国際医療研究センター病院)
Japanese Journal of Clinical Oncology, Volume 49, Issue 6, June 2019, Pages 554–558,
Plasma ctDNA monitoring during epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor treatment in patients with EGFR-mutant non-small cell lung cancer (JP-CLEAR trial) (臼井 一裕:NTT東日本関東病院)
肺癌
ESMO Open Cancer Horizons. DOI: 10.1136/esmoopen-2017-000214 / Published 14 September 2017
Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study (後藤 悌:国立がん研究センター中央病院)
日本臨床腫瘍学会 / 2015年7月
第54回日本肺癌学会 / 2013年11月
上皮性増殖因⼦受容体変異陽性(EGFRm+)肺癌に対するチロシンキナーゼ阻害剤での初回治療の観察研究
(金 永学:京都大学医学部附属病院)
肺癌
Anticancer Research March 2017 vol. 37 no. 3 1507-1513
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting (葉 清隆:国立がん研究センター東病院)
第54回日本肺癌学会 / 2013年11月
進行・再発非小細胞肺癌(NSCLC)初回化学療法終了後患者の維持療法・二次療法実施に関する観察研究、中間報告
(堀田勝幸:岡山大学病院)
5th Asia Pacific Lung Cancer Conference / 2012年11月
第53回日本肺癌学会 / 2012年11月
進行・再発非小細胞肺癌初回治療終了後患者の観察研究(SAPPHIRE研究)、初回報告
(森 清志:栃木県立がんセンター)
大腸癌
胃癌
ESMO-GI/2022年6月
Impact of Salvage Chemotherapy after Nivolumab Therapy (NIVO):A Sub-Study of REVIVE(松岡 宏:藤田医科大学病院)
日本臨床腫瘍学会/2022年2月17日
REVIVE study: An Observational Study in Chemotherapy ( CTx ) after Nivolumab (NIVO) for Advanced Gastric Cancer (AGC)(坂本 康寛:大崎市民病院)
ASCO-GI/2022年1月21日
REVIVE study: A Prospective Observational Study in Chemotherapy (CTx) after Nivolumab (NIVO) Therapy for Advanced Gastric Cancer (AGC)(松島 知広:埼玉県立がんセンター)
Future Oncology, Volume 17, Issue 8 / Published online: 21 September 2020
REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer(成田 有季哉:愛知県がんセンター)
日本臨床腫瘍学会/2019年7月18日
Chemotherapy after progREssiVe dIsease of niVolumab (NIV) thErapy (REVIVE study)(成田 有季哉:愛知県がんセンター)
日本胃癌学会/2019年2月28日
Trial in Progress: Chemotherapy after progREssiVe dIsease of niVolumab thErapy (REVIVE study)(成田 有季哉:愛知県がんセンター)
ASCO-GI/2019年1月
REVIVE study: Prospective observational study of efficacy and safety in chemotherapy after progREssiVe dIsease of niVolumab (NIV) thErapy for metastatic gastric cancer (mGC) (成田 有季哉:愛知県がんセンター)
肝細胞癌
日本肝癌研究会/2022年5月13日
切除不能肝細胞癌に対するレンバチニブ投与によるコンバージョン⼿術 -多施設前向き研究LENS-HCC trial- Multicenter, single-arm trial to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial(日髙 匡章:長崎大学)
ASCO-GI/2022年1月21日
Multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: LENS-HCC trial(多田 正晴:兵庫医科大学病院)
日本癌治療学会/2019年10月25日
Multicenter, single-arm trial of lenvatinib followed by surgical resection for initially unresectable hepatocellular carcinoma: LENS-HCC trial(市田 晃彦:東京大学医学部附属病院)
前立腺癌
Japanese Journal of Clinical Oncology / 2021年11月
A randomized controlled trial evaluating the effect of low-dose chlormadinone in patients with low-risk prostate cancer: PROSAS study(杉元幹史:香川大学医学部附属病院)
第108回日本泌尿器科学会総会 / 2020年12月
低リスク前立腺癌患者を対象とした低用量クロルマジノンの監視療法継続率に対する効果を検討する多施設共同、プラセボ対照、無作為化二重盲検群間比較試験 (PROSAS試験 )(鳥本 一匡:奈良県立医科大学)
腎癌
第54回日本癌治療学会学術集会 / 2016年10月
第104回日本泌尿器科学会総会 / 2016年4月23日
根治切除不能または転移性の腎細胞癌患者 に対する1st line TKI療法不応後の エベロリムスの有効性および安全性の検討 ― 多施設共同第Ⅱ相試験 ―(杉山貴之:浜松医科大学泌尿器科学講座)
CSP-A-TOP
J-05
Osteoporosis International; https://doi.org/10.1007/s00198-021-05996-2
A randomized, controlled trial of once-weekly teriparatide injection versus alendronate in patients at high risk of osteoporotic fracture: primary results of the Japanese Osteoporosis Intervention Trial-05. Hagino H, Sugimoto T, Tanaka S, Sone T, Nakamura T, Soen S, Mori S
J Bone Miner Metab ; 2020, 38, 412–417.
Design of a randomized trial of teriparatide followed by alendronate:Japanese Osteoporosis Intervention Trial‑05 (JOINT‑05). Tanaka S, Mori S, Hagino H, Sugimoto T
J-04
Arch Osteoporos. 2021 Dec 27;17(1):7. doi: 10.1007/s11657-021-01054-w.
Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05. Taguchi A, Uemura Y, Tanaka S, Ohta H, Mori S, Hagino H, Shiraki M, Nakamura T, Soen S; Adequate Treatment of Osteoporosis (A-TOP) research group.
J Bone Miner Metab; 2021, 39:668-677. doi: 10.1007/s00774-021-01208-3.
Risk factors for incident vertebral fractures in osteoporosis pharmacotherapy: a 2-year, prospective, observational study.Hiroshi Hagino , Yukari Uemura , Satoshi Mori , Teruki Sone , Hiroaki Ohta , Toshitaka Nakamura
Curr Med Res Opin; 2020,36(11),1847-1859. doi: 10.1080/03007995.2020.1816537. Epub 2020 Sep 14
Randomized head-to-head comparison of minodronic acid and raloxifene for fracture incidence in postmenopausal Japanese women: the Japanese Osteoporosis Intervention Trial (JOINT)-04. Yukari Uemura , Teruki Sone , Shiro Tanaka , Teruhiko Miyazaki , Mayumi Tsukiyama , Akira Taguchi , Satoshi Soen , Satoshi Mori , Hiroshi Hagino , Toshitsugu Sugimoto , Masao Fukunaga , Hiroaki Ohta , Toshitaka Nakamura , Hajime Orimo , Masataka Shiraki , Adequate Treatment of Osteoporosis (A-TOP) Research Group
J Bone Miner Metab ; 2019,37, 886–892.
Incidence of osteonecrosis of the jaw in Japanese osteoporosis patients taking minodronic acid. Taguchi A, Uemura Y, Imai T, Tanaka S, Ohta H, Nakamura T, Orimo H, Sugimoto T, Soen S, Shiraki M ,Adequate Treatment of Osteoporosis(A-TOP) research group.
J Bone Miner Metab; 2019,37(3),491-495. doi: 10.1007/s00774-018-0942-z. Epub 2018 Jul 17.
Study design of multi-center, open-label randomized controlled, head-to-headtrial comparing minodronic acid and raloxifene: Japanese Osteoporosis Intervention Trial (JOINT)-04. Uemura Y, Tanaka S, Miyazaki T, Tsukiyama M, Sone T, Taguchi A, Soen S, Moei S, Hagino H, Sugimoto T, Fukunaga M, Ohta H, Nakamura T, Orimo H, Shiraki M, Adequate Treatment of Osteoporosis (A-TOP) research group.
J-03
Osteoporos Int; 2017,28(6),1893-1901.DOI 10,1007/S 00198-017-3966-7
Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial. Imai T, Tanaka S, Kawakami K, Miyazaki T, Hagino H, Shiraki M, for the A-TOP(Adequate Treatment of Osteoporosis) Research Group.
J Bone Miner Metab ; 2017,35(4);385-395.DOI 10.1007/s00774-016-0768-5
Comparison of concurrent treatment with vitamin K2 and risedronate compared with treatment with risedronate alone in patients with osteoporosis: Japanese Osteoporosis Intervention Trial-03. Tanaka S, Miyazaki T, Uemura Y, Miyakawa N, Gorai I, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki M.
J Bone Miner Metab; 2014,32(3), 298-304.
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Tanaka S, Miyazaki T, Uemura Y, Kuroda T, Miyakawa N, Nakamura T, Fukunaga M, Ohashi Y, Ohta H, Mori S, Hagino H, Hosoi T, Sugimoto T, Itoi E, Orimo H, Shiraki
J-02
J Orthop Sci. ; 2020,S0949-2658(20)30332-8.
Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy. Eiji Itoi , Yukari Uemura , Hiroaki Ohta , Toshitaka Nakamura , Masao Fukunaga , Hajime Orimo , Masataka Shiraki .
Clin Therap; 2014,36(2),225-235.
Serum 25 hydroxyvitamin D level as an independent determinant of quality of life in osteoporosis with high risk for fracture. Ohta H, Uemura Y, Nakamura T, Fukunaga M, Ohashi Z, Hosoi T, Mori S, Sugimoto T, Itoi E, Orimo H, Shiraki M for the Adequate Treatment of Osteoporosis.(A-TOP)research group.
J Bone Miner Metab; 2015,33(6):,642-650.
Comparison of expert and nonexpert physicians in the assessment of vertebral fractures using the semiquantitative method in Japan. Uemura Y, Miyakawa N, Orimo H, Shiraki M, Nakamura T, Mori S.
Curr Med Res Opin; 2011,27(6),1273-84.
Effects of alendronate plus alfacalcidol in osteoporosis patients with a high risk of fracture: the Japanese Osteoporosis Intervention Trial (JOINT)- 02. Orimo H, Nakamura T, Fukunaga M, Ohta H, Hosoi T, Uemura Y, Kuroda T, Miyakawa N, Ohashi Y, Shiraki M; A-TOP (Adequate Treatment of Osteoporosis)research group
J Bone Miner Metab; 2011,29(1),37-43.
Design of a pragmatic approach to evaluate the effectiveness of concurrent treatment for the prevention of osteoporotic fractures: rationale, aims and organization of a Japanese Osteoporosis Intervention Trial(JOINT) initiated by the Research Group of Adequate Treatment of Osteoporosis (A-TOP). Shiraki M, Kuroda T, Hosoi T, Ohashi Y, Ohta H, Fukunaga M, Nakamura T, Orimo H et al.
A-01
Jpn J Pharmacoepidemiol;21(1);13-19,2016,DOI.org/10.3820/jjpe.21.13
Validation Study of Claims-based Definitions of Suspected Atypical Femoral Fractures Using Clinical Information. Tanaka S, Hagino H, Ishizuka A, Miyazaki T, Yamamoto T, Hosoi T.
CSP-LD
LD-16
Journal of Bone and Mineral Metabolism volume 38, pages230–239(2020)
Journal of Clinical Trials:2017, 7:6 DOI: 10.4172/2167-0870.1000336
LD-15
American Journal of Kidney Diseases :August 31, 2018
LD-12
Circulation Journal: 2015 Volume 79 Issue 5 Pages 981-990
LD-11
Heart and Vessels volume 30, pages805–817(2015)
LD-10
Digestive Diseases and Sciences volume 63, pages1910–1919(2018)
LD-09
International heart journal/2018 Volume 59 Issue 2 Pages 315-320
American Heart Association(AHA)_ Late breaking/ 2017年11月13日
Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Takeshi Kimura, Teruo Inoue, Isao Taguchi, Hiroshi Iwata, Satoshi Iimuro, Takafumi Hiro, Yoshihisa Nakagawa, Yukio Ozaki, Yasuo Ohashi, Hiroyuki Daida, Hiroaki Shimokawa, Ryozo Nagai, on behalf of the REAL-CAD Study Investigators
LD-08
American Heart Association(AHA)_Late breaking/2018年11月10日
Ezetimibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 Years Old or Over) Patients With Elevated LDL-Cholesterol.
Yasuyoshi Ouchi , Hidenori Arai, Jun Sasaki, Koutaro Yokote, Masanari Kuwabara, Kazumasa Harada, Takumi Imai, Shiro Tanaka, Yasuo Ohashi, Hideki Ito on behalf of the EWTOPIA investigators
LD-07
Journal of Atheroscler Thromb. 2017 Jan 1; 24(1): 77–94.doi: 10.5551/jat.35626
疫学調査
Kidney International (2017) 91, 227–234
Clinical and Experimental Nephrology volume 21, pages446–456(2017)
疫学調査
Annals of Vascular Diseases/ 2019 Jun 25; 12(2): 182–186.
疫学調査
日本糖尿病学会・2009年5月
米国糖尿病学会 ニューオリンズ・2009年6月
CSP-HOR
CSP-CCR
C-10
第66回日本産科婦人科学会学術講演会/2014
子宮頸がん予防に対する女性医療従事者の意識調査・入江琢也
C-09
日本性感染症学会誌 2013; 24(1): 103-9/2013
尖圭コンジローマ患者のQOL調査:多施設共同研究 (J-HERS Study)・入江, et al.
第65回 日本産科婦人科学会学術講演会/2013
尖圭コンジローマに罹患した日本人女性のQuolity of Life (QOL) 調査: 多施設共同研究 (J-HERS Study)・伊藤富士子
第25回 日本性感染症学会学術大会/2012
尖圭コンジローマ患者のQOL調査・入江琢也
28th International Papillomavirus Conference (IPV)/2012
Multi-Center Study (J-HERS) for Quality of Life of Women with Genital Warts in Japan -Interim Report-・F Ito
C-08
第52回 日本臨床細胞学会 秋季大会/2013
日本における高リスク型HPVを再考する・伊藤富士子
第54回 日本臨床細胞学会総会 春季大会/2013
子宮頚部細胞診とHPV感染および型別診断の大規模研究:J-HERS多施設共同研究・前濱俊之
第54回 日本臨床細胞学会総会 春季大会/2013
子宮頚部液状細胞診とHPV-DNA検査併用の意義:J-HERS大規模調査・笹川寿之
第65回 日本産科婦人科学会学術講演会/2013
日本人女性の子宮頚部に感染するHPV型と細胞診談の大規模研究:多施設共同研究 (J-HERS Study)・前濱俊之
第25回 日本性感染症学会学術大会/2012
HPV DNA型調査・前濱俊之
28th International Papillomavirus Conference (IPV)/2012
A multii-center study (J-HERS) for prevalent HPV genotypes and abnormal cytology in young Japanese women・T Sasagawa
C-06
27th International Papillomavirus Conference (IPV)/2011
Estimation of the incidence of genital wart, cervical intraepithelial neoplasia and cervical cancer in Japan (J-HERS)・T Sasagawa
C-05
日本呼吸器学会/2014
呼吸器疾患未治療の日本人COPD患者に対するガイドライン薬物治療効果の検討・瀬戸口靖弘(東京医科大学病院)
その他
日本臨床試験学会 第8回学術集会総会 IN 大阪
メイキング・ チェックリスト ~臨床研究への挑戦 ~
○浅野 昌彦 、荒井 秀和、齋藤 由紀、寺本 藍、 長尾 典明、村田 翔、吉田 和史、西谷 政昭
第15回 CRCと臨床試験の在り方を考える会議 2015 in KOBE
医師主導臨床研究の試験運営における財団の果たす役割~臨床研究のパイオニアとしての挑戦
○井ノ上仁子、中里淳子、秋田美穂、浅野昌彦、西村尚子、西谷政昭、宮崎輝彦